{{Infobox drug | drug_name = Belapectin | synonyms = {{ubl|GR-MD-02|Galactoarabino-rhamnogalacturonate}} | INN = | type = <!-- empty --> | image = | alt = | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = | ATCvet = | ATC_prefix = <!-- 'none' if uncategorised --> | ATC_suffix = <!-- Legal status --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 --> | legal_BR_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA_comment = | legal_DE = <!-- Anlage I, II, III or Unscheduled --> | legal_DE_comment = | legal_NZ = <!-- Class A, B, C --> | legal_NZ_comment = | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> | legal_UK_comment = | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US_comment = | legal_EU = | legal_EU_comment = | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> | legal_UN_comment = | legal_status = Investigational <!-- Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = <!-- Identifiers --> | CAS_number = 1980787-47-0 | CAS_number2 = 1604015-18-0 | UNII = K7ODU55HT6 | PubChem = | DrugBank = DB15125 <!-- Chemical and physical data --> | IUPAC_name = α-<small>D</small>-Galacturono-α-<small>D</small>-galacto-β-<small>D</small>-galacto-6-deoxy-α-<small>L</small>- manno-α-<small>L</small>-arabinan, (1→2),(1→3),(1→4)-, methyl ester | chemical_formula = | molecular_weight = }}
'''Belapectin''' (also known as GR-MD-02) is a galectin-3 inhibitor developed by Galectin Therapeutics for the treatment of non-alcoholic steatohepatitis.<ref>{{cite journal |last1=Al Attar |first1=Atef |last2=Antaramian |first2=Ani |last3=Noureddin |first3=Mazen |title=Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis |journal=Expert Review of Clinical Pharmacology |date=3 April 2021 |volume=14 |issue=4 |pages=457–464 |doi=10.1080/17512433.2021.1894127|pmid=33612037 }}</ref><ref>{{Cite journal |last1=Kram |first1=Michael |date=Feb 27, 2023 |title=Galectin-3 inhibition as a potential therapeutic target in non-alcoholic steatohepatitis liver fibrosis |journal=World J Hepatol |volume=15 |issue=2 |pages=201–207 |doi=10.4254/wjh.v15.i2.201 |pmid=36926236 |pmc=10011901 |doi-access=free }}</ref><ref>{{cite journal |last1=Slack |first1=R.J. |last2=Mills |first2=R. |last3=Mackinnon |first3=A.C. |title=The therapeutic potential of galectin-3 inhibition in fibrotic disease |journal=The International Journal of Biochemistry & Cell Biology |date=January 2021 |volume=130 |article-number=105881 |doi=10.1016/j.biocel.2020.105881|doi-access=free |pmid=33181315 }}</ref><ref>{{cite journal |last1=Tapper |first1=Elliot B. |last2=Ufere |first2=Nneka N. |last3=Huang |first3=Daniel Q. |last4=Loomba |first4=Rohit |title=Review article: current and emerging therapies for the management of cirrhosis and its complications |journal=Alimentary Pharmacology & Therapeutics |date=May 2022 |volume=55 |issue=9 |pages=1099–1115 |doi=10.1111/apt.16831 |pmid=35235219 |url=https://doi.org/10.1111/apt.16831 |language=en |issn=0269-2813|pmc=9314053 }}</ref> In a phase 2b/3 trial belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension.<ref>{{Cite journal |date=10 May 2025 |title=Belapectin at 2 mg/kg/LBW reduces varices development in MASH cirrhosis with portal hypertension: results from the NAVIGATE trial |url=https://www.easlcongress.eu/wp-content/uploads/2025/04/EASL-Congress-2025-_-LB-Abstracts.pdf |journal=EASL Congress |volume=2025}}</ref>
==References== {{reflist}}
Category:Lectins Category:Experimental drugs developed for non-alcoholic fatty liver disease
{{pharma-stub}}